ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

In Brief: NCI to Extend Frederick contract To SAIC; Klausner, Gallin, Gail Elected to IOM

October 24, 1996

Center Directors Solidly opposed To Core grant changes, Ask Upton, NCAB To Find Other Solutions

November 11, 1977

Radio-Immunotherapy Advances May Rival Those With Drugs

April 16, 1976

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

April 25, 2014

Gallo Inquiry Complete; NCAB’s AIDS Committee Plans Q&A Session

June 12, 1992

Republican Congress To Shift Priorities, But Cancer May Get New Opportunities

November 18, 1994